Abstract:OBJECTIVE Whether combined radiation and tyrosine kinase inhibitor (TKI) therapy in non–small cell lung cancer (NSCLC) patients with brain metastases (BMs) and epidermal growth factor receptor (EGFR) mutations confers additional benefits over TKI therapy alone remains a matter of debate. The goal of this study was to compare outcomes between combined TKI therapy with stereotactic radiosurgery (SRS) versus TKI therapy alone in NSCLC patients with BMs and EGFR mutations. METHODS Consecutive cases of NSCLC patients with EGFR mutations and BMs treated with TKIs were selected for inclusion in this study. Patients were categorized into two groups based on SRS: TKI therapy alone (group I) and combined SRS and TKI therapy (group II). Patients who had SRS or TKI as salvage therapy and those with prior radiation treatment for BMs were excluded. Tumor control (< 10% increase in tumor volume) and overall survival (OS) rates were compared using Kaplan-Meier analyses. Independent predictors of tumor control and OS were identified using multivariable Cox regression analyses. RESULTS The study cohort comprised 280 patients (n = 90 in group I and n = 190 in group II). Cumulative tumor control rates were higher in group II than in group I (79.8% vs 31.2% at 36 months, p < 0.0001). Cumulative OS rates were comparable between groups I and II (43.8% vs 59.4% at 36 months, p = 0.3203). Independent predictors of tumor control were older age (p < 0.01, HR 1.03), fewer BMs (p < 0.01, HR 1.09), lack of extracranial metastasis (p < 0.02, HR 0.70), and combined SRS and TKI therapy (p < 0.01, HR 0.25). Independent predictors of OS were fewer BMs (p < 0.01, HR 1.04) and a higher Karnofsky Performance Status score (p < 0.01, HR 0.97). CONCLUSIONS Although the OS rate did not differ between TKI therapy with and without SRS, the addition of SRS to TKI therapy resulted in improvement of intracranial tumor control. The lack of effect on survival rate with the addition of SRS may be attributable to extracranial disease progression. The addition of SRS to TKI therapy is recommended for intracranial disease control in NSCLC patients with BMs and EGFR mutations. Potential benefits may include prevention of neurological deficits and seizures. Future prospective studies may help clarify the clinical outcome benefits of SRS in these patients.

Concurrent Brain Radiotherapy and EGFR-TKI May Improve Intracranial Metastases Control in Non-Small Cell Lung Cancer and Have Survival Benefit in Patients with Low DS-GPA Score.

Early Radiation Therapy Combined with Egfr-Tki is Associated with Longer Survival in Egfr-Mutated Non-Small Cell Lung Cancer Patients with Brain Metastases

Radiotherapy plus EGFR TKIs in non‐small cell lung cancer patients with brain metastases: an update meta‐analysis

1439P Brain Radiotherapy Combined with Camrelizumab and Platinum-Based Chemotherapy As First-Line Treatment for Advanced NSCLC with Brain Metastases: A Multicenter, Open-Label, Single-Arm, Phase II Study

[Prognostic Analysis of EGFR-TKIs Combined with Gamma Knife in EGFR-mutant Lung Adenocarcinoma with Brain Metastasis].

Impact of Different Timing of Radiation Therapy in Patients with Brain Metastases from Epidermal Growth Factor Receptor-Mutant Non-Small Cell Lung Cancer.

Impact of Different Timing of Radiation Therapy on Patients with Brain Metastases from Epidermal Growth Factor Receptor-Mutant Non–small Cell Lung Cancer

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Treatment of Brain Metastasis from Non-Small Cell Lung Cancer

Value and significance of brain radiation therapy during first-line EGFR-TKI treatment in lung adenocarcinoma with EGFR sensitive mutation and synchronous brain metastasis: Appropriate timing and technique

EGFR TKIs Plus WBRT Demonstrated No Survival Benefit Other Than That of TKIs Alone in Patients with NSCLC and EGFR Mutation and Brain Metastases

The Efficacy of Upfront Intracranial Radiation with TKI Compared to TKI Alone in the NSCLC Patients Harboring EGFR Mutation and Brain Metastases.

Radiotherapy for Asymptomatic Brain Metastasis in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Without Prior Tyrosine Kinase Inhibitors Treatment: a Retrospective Clinical Study

The efficacy of upfront craniocerebral radiotherapy and epidermal growth factor receptor-tyrosine kinase inhibitors in patients with epidermal growth factor receptor-positive non-small cell lung cancer with brain metastases

Combined stereotactic radiosurgery and tyrosine kinase inhibitor therapy versus tyrosine kinase inhibitor therapy alone for the treatment of non–small cell lung cancer patients with brain metastases

Optimal Timing of Hypofractionated Stereotactic Radiotherapy for Epidermal Growth Factor Receptor-Mutated Non-Small-cell Lung Cancer Patients with Brain Metastases.

EGFR-TKI Plus Brain Radiotherapy Versus EGFR-TKI Alone in the Management of EGFR-mutated NSCLC Patients with Brain Metastases.

Combination Therapy of Brain Radiotherapy and EGFR-TKIs is More Effective Than TKIs Alone for EGFR-mutant Lung Adenocarcinoma Patients with Asymptomatic Brain Metastasis

Improved Survival Outcome with Not-Delayed Radiotherapy and Immediate PD-1/PD-L1 Inhibitor for Non-Small-cell Lung Cancer Patients with Brain Metastases.

Concurrent versus sequential whole brain radiotherapy and TKI in EGFR-mutated NSCLC patients with brain metastasis: A single institution retrospective analysis.

EGFR-TKI Therapy for Patients with Brain Metastases from Non-Small-cell Lung Cancer: a Pooled Analysis of Published Data

EGFR-TKIs Plus Bevacizumab Demonstrated Survival Benefit Than EGFR-TKIs Alone in EGFR-mutant NSCLC Patients with Multiple Brain Metastases